Scientists have identified a gene - FOXC1 - that, if switched on, causes more aggressive cancer in a fifth of acute myeloid leukaemia (AML) patients, according to a Cancer Research UK study* published in the journal Cancer Cell, today.
The FOXC1 gene is normally switched on during embryonic development and is needed to turn cells into specialised tissues, like the eyes, kidney, brain and bone.
But this new research found that in certain patients with AML - a type of blood cancer that affects white blood cells and the bone marrow - this gene was wrongly switched on inside the patient's cancer cells.
When it is switched on in blood cell tissue, FOXC1 stunts the development of blood cells and stops them maturing into normal specialised blood cells.
This triggers the cancer to be more aggressive, as young cells are able to replicate more than mature cells - causing cancer cells to grow faster and become more difficult to treat.
Around 2,900 people are diagnosed with AML each year in the UK. Of these, around 20 per cent would have had the FOXC1 gene wrongly switched on in their cancer.
Dr Tim Somervaille, lead author from the Cancer Research UK Manchester Institute at The University of Manchester, said: "This is an important finding which helps us understand how acute myeloid leukaemia develops and why some cases of AML are more aggressive than others. Here, instead of being faulty or mutated, this normal gene is turned on in the wrong place at the wrong time which makes the cancer grow more rapidly.
"There are certain situations where this gene is necessary, as in the development of the eye and skeleton before birth. But when it's switched on in the wrong tissue, it causes more aggressive forms of leukaemia."
Nell Barrie, senior science communication manager at Cancer Research UK, said: "It's essential that we continue to research basic biology to further understand how cells become cancerous. In this study, identifying a specific gene behind more aggressive forms of acute myeloid leukaemia could give clues for new ways to personalise treatments for select patients. The better we understand the nuts and bolts of each cancer, the sooner we can find new ways to stop it."
For more information on acute myeloid leukaemia visit our website or call our Cancer Research UK nurses on 0808 800 4040.
For media enquiries contact Stephanie McClellan in the Cancer Research UK press office on 020 3469 5314 or, out of hours, on 07050 264 059.
Notes to editor:
- Somerville et al. Frequent derepression of the mesenchymal transcription factor gene FOXC1 in acute myeloid leukemia. Cancer Cell
This study was funded by Cancer Research UK with additional funding from the charity Bloodwise, which recently changed its name from Leukaemia & Lymphoma Research.
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.